Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Affymetrix, Inc. (AFFX) A Good Stock To Buy?

Page 1 of 2

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Affymetrix, Inc. (NASDAQ:AFFX) from the perspective of those elite funds.

Affymetrix, Inc. (NASDAQ:AFFX) was in 24 hedge funds’ portfolios at the end of the third quarter of 2015. Affymetrix, Inc. (NASDAQ:AFFX) has experienced an increase in hedge fund sentiment of late. There were 22 hedge funds in our database with Affymetrix, Inc. (NASDAQ:AFFX)positions at the end of the previous quarter. At the end of this article, we will also compare Affymetrix, Inc. (NASDAQ:AFFX) to other stocks, including Yadkin Financial Corp (NYSE:YDKN), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), and General Communication, Inc. (NASDAQ:GNCMA) to get a better sense of its popularity.

Follow Affymetrix Inc (NASDAQ:AFFX)
Trade (NASDAQ:AFFX) Now!

At the moment, there are many gauges market participants put to use to grade stocks. A duo of the most innovative gauges are hedge fund and insider trading indicators. Our experts have shown that, historically, those who follow the top picks of the best money managers can outclass the market by a very impressive amount (see the details here).

Keeping this in mind, let’s go over the latest action encompassing Affymetrix, Inc. (NASDAQ:AFFX).

What have hedge funds been doing with Affymetrix, Inc. (NASDAQ:AFFX)?

At the end of Q3, a total of 24 of the hedge funds tracked by Insider Monkey were bullish on this stock, an increase of 9% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of noteworthy hedge fund managers who were upping their stakes significantly (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Samuel Isaly’s OrbiMed Advisors has the number one position in Affymetrix, Inc. (NASDAQ:AFFX), worth close to $64.1 million, amounting to 0.6% of its total 13F portfolio. Coming in second is Levin Capital Strategies, led by John A. Levin, holding a $26.7 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Remaining hedge funds and institutional investors that hold long positions contain Renaissance Technologies, Israel Englander’s Millennium Management, and John Overdeck and David Siegel’s Two Sigma Advisors.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!